Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.58 |
| ▸ | F2 | P00734 | 1/20 | 0.58 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.56 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.52 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5559781 | 1.00 | DPP4 (0.58) | DPP4F2ADRA2AADRA2CLMNA | |
| SCHEMBL830 | 1.00 | — | — | |
| SCHEMBL42904 | 1.00 | — | — | |
| SCHEMBL4916236 | 1.00 | DPP4 (0.58) | DPP4F2ADRA2AADRA2CLMNA | |
| SCHEMBL42393 | 1.00 | — | — | |
| SCHEMBL24932018 | 1.00 | DPP4 (0.58) | DPP4F2ADRA2AADRA2CLMNA | |
| SCHEMBL29380238 | 1.00 | — | — | |
| Ammonia Solution, Strong SCHEMBL3867318 | 0.97 | DPP4 (0.55) | DPP4F2ADRA2AADRA2CLMNA | |
| Hydrochloric Acid SCHEMBL241514 | 0.97 | ALDH1A1 (0.58) | DPP4F2ADRA2AADRA2CLMNA | |
| Hydrochloric Acid SCHEMBL4602345 | 0.97 | ALDH1A1 (0.58) | DPP4F2ADRA2AADRA2CLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7186710-B2 | Phthalazinones | ALTANA PHARMA AG (DE) | 2007-03-06 | — | — | US | disclosed |
| US-20060166995-A1 | Piperidine-n-oxide-derivatives | ALTANA PHARMA AG (DE) | 2006-07-27 | — | — | US | disclosed |
| US-20060094710-A1 | Piperidine-pyridazones and phthalazones as pde4 inhibitors | ALTANA PHARMA AG (DE) | 2006-05-04 | — | — | US | disclosed |
| US-7022696-B2 | Piperazino-derivatives and their use as PDE4 inhibitor | ALTANA PHARMA AG (DE) | 2006-04-04 | — | — | US | disclosed |
| US-6933296-B2 | Compounds effective as β2-adrenoreceptor agonists as well as PDE4-inhibitors | ALTANA PHARMA B.V. (NL) | 2005-08-23 | — | — | US | disclosed |
| EP-1556049-A1 | PIPERIDINE-PYRIDAZONES AND PHTHALAZONES AS PDE4 INHIBITORS | ALTANA Pharma AG (DE) | 2005-07-27 | — | — | EP | disclosed |
| EP-1542987-A1 | PIPERIDINE-N-OXIDE-DERIVATIVES | ALTANA Pharma AG (DE) | 2005-06-22 | — | — | EP | disclosed |
| US-20040132721-A1 | Piperazino-derivatives and their use as pde4 inhibitor | ATLANTA PHARMA AG (DE) | 2004-07-08 | — | — | US | disclosed |
| US-20040127707-A1 | PDE4/7 inhibitors useful in treatment of airway disorders, autoimmune system disorders, skin disorders, arthritis, nerve system disorders | ALTANA PHARMA AG (DE) | 2004-07-01 | — | — | US | disclosed |
| WO-2004017974-A1 | PIPERIDINE-PYRIDAZONES AND PHTHALAZONES AS PDE4 INHIBITORS | ALTANA PHARMA AG (DE) | 2004-03-04 | — | — | WO | disclosed |
| WO-2004018450-A1 | PIPERIDINE-N-OXIDE-DERIVATIVES | ALTANA PHARMA AG (DE) | 2004-03-04 | — | — | WO | disclosed |
| EP-1385838-A1 | PIPERAZINO-DERIVATIVES AND THEIR USE AS PDE4 INHIBITOR | ALTANA Pharma AG (DE) | 2004-02-04 | — | — | EP | disclosed |
| US-20030195215-A1 | Compounds effective as beta-2 adrenoreceptor agonists as well pde4-inhibitors | ALTANA PHARMA B.V. (NL) | 2003-10-16 | — | — | US | disclosed |
| WO-2002085885-A1 | PIPERAZINO-DERIVATIVES AND THEIR USE AS PDE4 INHIBITOR | ALTANA PHARMA AG (DE) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127707-A1 | PDE4/7 inhibitors useful in treatment of airway disorders, autoimmune system disorders, skin disorders, arthritis, nerve system disorders | PDE4A, PDE4B, PDE7B | DPP4 82/4885F2 4668/4885ADRA2A 751/4885 |
| US-20060166995-A1 | Piperidine-n-oxide-derivatives | PDE4A, PDE3A, PDE2A | DPP4 44/4885F2 4488/4885ADRA2A 140/4885 |
| US-20060094710-A1 | Piperidine-pyridazones and phthalazones as pde4 inhibitors | PDE4A, PDE4B, PDE3A | DPP4 14/4885F2 4542/4885ADRA2A 712/4885 |
| US-20040132721-A1 | Piperazino-derivatives and their use as pde4 inhibitor | PDE4A, PDE4B, PDE3A | DPP4 27/4885F2 3014/4885ADRA2A 129/4885 |
| US-20030195215-A1 | Compounds effective as beta-2 adrenoreceptor agonists as well pde4-inhibitors | ADRB1, ADRB2, ADRA1D | DPP4 782/4885F2 4767/4885ADRA2A 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.